One Center • One Focus • One Team

Dr. Wade Smith

HomeDr. Wade Smith

About Dr. Wade Smith

Dr. Wade Smith is a medical oncologist that specializes in the treatment of breast cancer as well as benign and malignant blood disorders. He helps helps breast cancer patients in Orange County and the Temecula Valley.

Can Stress Cause Cancer?

Cancer patients are often left with feelings of extreme helplessness. This experience of hopelessness, in addition to feeling overwhelmed by social and often financial constraints, can culminate in a state of severe psychosocial stress – or simply “stress.” While stress in and of itself can significantly detract from quality of life, research has also linked stress in cancer patients with decreased survival.

What is “Stress?”

In 1936, an Austro-Hungarian scientist named Hans Selye published the first treatise on stress. Through a combination of lab work and observation, he discovered what he called a “non-specific response of the body to any demand for change,” but which he later dubbed “stress.” The stress response […]

What is “Chemo Brain”?

“Chemo brain” is a side effect of cancer treatment. It mostly affects patients who receive chemotherapy, but it can affect other cancer patients as well. Patients describe it as a “fog” that makes it hard to think clearly. Fortunately, “chemo brain” only affects patients while they’re being treated for cancer. Symptoms appear when treatment starts and fades after it’s finished. Though sometimes these symptoms can linger for several months or several years following treatment, most patients make a full recovery and suffer no or very minimal long-term side effects.

What are the Symptoms of “Chemo Brain?”

“Chemo brain” impairs your ability to think. Some of the most common symptoms are:

  1. Difficulty […]
By |September 16, 2016|Categories: Breast Cancer|0 Comments

Chemotherapy Side Effects in Breast Cancer Patients

Medical advancements allow us to treat breast cancer more effectively than ever before. However, side effects can occur as a result of treatment. Many breast cancer patients receive some combination of surgery, radiation therapy and chemotherapy. Chemotherapy side effects can range from being a temporary nuisance to having a sustained negative impact on quality of life. As oncologists, it is our job to help patients avoid, lessen or completely eliminate such side effects. […]

By |November 9, 2015|Categories: Oncology|0 Comments

Breastlink Partners with Researchers to Explore Atezolizumab in Triple-Negative Breast Cancer Patients

Breastlink has partnered with researchers to explore an investigational cancer immunotherapy called atezolizumab (MPDL3280A) in the treatment of metastatic triple-negative breast cancer. In early-stage trials, atezolizmab was effective in patients previously treated for triple-negative breast cancer. A new trial will investigate atezolizumab with chemotherapy in metastatic triple-negative breast cancer patients who have not received prior systemic therapy for incurable disease. […]

Breast Cancer Incidences Expected to Grow

Over the next several decades, the incidence of breast cancer is expected to rise. We will also witness shifting patterns regarding the types of breast cancer diagnosed and ages of women diagnosed. As these changes occur, it is critical for breast cancer treatment teams to consider each case individually.

It is necessary for physicians to consider each patient’s disease on a case-by-case basis. Every breast cancer and every woman diagnosed with breast cancer is different. It is critical that women receive care tailored to their individual needs. A multidisciplinary team of breast cancer specialists will consider all possible options according to cancer subtype and personal goals to ensure women receive the […]

Palbociclib & Advanced ER-Positive Breast Cancer Treatment

ibrance palbociclib er positive breast cancerWomen with advanced estrogen receptor-positive (ER-positive) breast cancer now have a new treatment option at their disposal. The FDA recently approved a drug called palbociclib (Ibrance®) as a frontline treatment for women with ER-positive, HER2-negative metastatic breast cancer.

Palbociclib granted accelerated approval

Research investigating palbociclib has delivered promising results. Based on the phase 2 results of the PALOMA-1 clinical trial, palbociclib was granted “breakthrough therapy designation” by the FDA. On February 3, the FDA announced it had approved palbociclib through an accelerated process because clinical data showed clear potential for clinical benefit to patients.

Palbociclib <a href=[…]

By |February 22, 2015|Categories: Cancer News, Oncology|0 Comments

SABCS 2014: ER Positive Breast Cancer Treatments

As the 37th annual San Antonio Breast Cancer Symposium (SABCS) drew to a close, a range of intriguing clinical observations and long-awaited trial updates had made the event a valuable experience for investigators and attendees alike. Among some of the most interesting updates, in my opinion, were advancements in treatments for estrogen receptor-positive (ER-positive) breast cancer, premenopausal breast cancers and advanced breast cancers.

San Antonio Breast Cancer Symposium 2014

ER Positive Breast Cancers

Results from the FERGI trial were presented at this year’s meeting. This trial is investigating the new agent pictilisib, which belong to a new class of drugs called PI3K inhibitors that […]

SABCS 2014: Estrogen Receptor Positive Treatments & More

The San Antonio Breast Cancer Symposium (SABCS) is one of the world’s premier forums on breast cancer prevention, screening and treatments. Leading experts on breast cancer from various backgrounds gather every year at the SABCS in an effort to promote discussion and education around current trends in breast cancer research.

Now in its 37th year, one of the major focuses of the 2014 SABCS will be on estrogen receptor positive breast cancer. For those interested in developments in this area and others, here is what to watch for.

San Antonio Breast Cancer Symposium 2014

Estrogen Receptor Positive Breast Cancers

In year’s past, HER2-positive breast cancers have […]

Advanced, HER2 Negative Breast Cancer Treatment

Different breast cancers behave in different ways, which necessitates separate treatment guidelines to address the individual characteristics of specific types of cancer. As knowledge evolves, treatment guidelines are updated to reflect up-to-date information about breast cancer. Recently, the American Society of Clinical Oncology (ASCO) published guidelines on the use of chemotherapy and targeted therapy in the treatment of patients with advanced, HER2 negative breast cancer.

What is HER2 Negative Breast Cancer?

HER2, or human epidermal growth factor receptor 2, is a protein that the human body develops to help regulate reproduction of the cells. Sometimes the gene responsible for developing this protein will over-replicate itself, which can result in overproduction of HER2. […]

Kadcyla Research Shows Promise in HER2 Positive Breast Cancer Treatment

Recent research into modern breast cancer therapies have driven major breakthroughs in antibody-drug conjugates, or “smart drugs,” which work by targeting cancer cells while minimizing damage to healthy body tissue.

Kadcyla, also known ado-trastuzumab emtansine (T-DM1), is one of the latest “smart drugs” 
to be FDA-approved in the treatment of women diagnosed with metastatic HER2-positive breast cancer. Kadcyla may also have potential as therapy after surgery where intent is curative.

Breastlink participated in the EMILIA trial, a key clinical trial that helped lead to swift approval of Kadcyla for HER2-positive advanced breast cancer. We also are participating in other ongoing trials to investigate additional uses for Kadcyla in […]

Load More Posts